We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Feb 2021 - 28 Feb 2021
Virtual Venue

New Device Shields Tissues During Laparoscopic Port Closure

By HospiMedica International staff writers
Posted on 24 Nov 2020
Print article
Image: The NeoClose AnchorGuard (Photo courtesy of Sharp Fluidics)
Image: The NeoClose AnchorGuard (Photo courtesy of Sharp Fluidics)
An innovative port site protector enables clinicians to close laparoscopic and robotic port sites without insufflation.

The Sharp Fluidics (San Francisco, CA, USA) NeoClose AnchorGuard is designed to deliver shielded port site closure after the patient’s insufflation gas has been vented, thus helping to reduce aerosolized virus potential. In addition, AnchorGuard provides clinicians the freedom to deliver NeoClose absorbable anchors safely through the fascia and deliver closure with up to 75% less tension on the tissue surrounding the site, compared to traditional closed loop approximation.

Clinical trials with the device have shown that using the NeoClose results in faster fascial closure times, decreased intraoperative needle depth, a shallower and more oblique trajectory of the suture needle, and decreased postoperative abdominal pain at one week, as compared to a standard suture passing device. The greater intraperitoneal needle depth required when using a standard suture passer can also increase the risk of iatrogenic visceral injuries, which sometimes go unnoticed and lead to postoperative complications.

“NeoClose brings a simple, intuitive, and reliable solution to assist the surgeon in closing port site defects following laparoscopic and robotic abdominal surgery. By utilizing bio-absorbable anchors with a pre-attached suture, NeoClose is changing the standard of care in port site closure,” said Douglas Rimer, President of Sharp Fluidics. “We look forward to bringing this technology to hospitals across the country to help reduce COVID-19 exposure in the operating room.”

“Current standard of care for port site closure after laparoscopic surgery can be improved. Herniation complications occur at a rate of six percent, but the actual rate is likely higher,” said Erik Wilson MD, professor surgery at the University of Texas Medical School (Houston, USA). “Complications such as small bowel strangulation or nerve entrapment are unacceptable. Now there's NeoClose.”

Current closed loop approximation methods can be technically challenging, requiring user skill and do not always result in consistent outcomes for the patient. Surgeons have continually grappled with locating sutures within the abdomen as well as managing post-operative issues such as pain and herniation, among other potential complications.

Related Links:
Sharp Fluidics


Print article

Channels

Business

view channel
Illustration

Hillrom Acquires Bardy Diagnostics to Expand into Ambulatory Cardiac Monitoring Segment

Hillrom (Chicago, IL, USA) has reached a definitive agreement to acquire Bardy Diagnostics, Inc. (BardyDx; Seattle, WA, USA) for a cash consideration of USD 375 million. The acquisition of BardyDx,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.